Preclinical development

Preclinical Development

File:Drug discovery cycle.svg

Diagram of the drug discovery cycle, illustrating the stages from discovery to preclinical development.

Preclinical development is a critical phase in the drug discovery process, where potential therapeutic compounds are tested extensively before they can proceed to clinical trials. This stage involves a series of laboratory and animal studies designed to assess the safety, efficacy, and pharmacokinetics of a drug candidate.

Objectives

The primary objectives of preclinical development are to:

• Determine the pharmacodynamics and pharmacokinetics of the drug candidate.
• Assess the toxicology and safety profile in animal models.
• Establish the formulation and stability of the drug.
• Gather data to support the design of clinical trials.

Key Components

Pharmacokinetics and Pharmacodynamics

Pharmacokinetics (PK) studies focus on how the drug is absorbed, distributed, metabolized, and excreted in the body. Pharmacodynamics (PD) studies, on the other hand, examine the biological effects of the drug and its mechanism of action. Together, PK/PD studies help in understanding the drug's behavior in biological systems.

Toxicology

Toxicology studies are conducted to identify any potential adverse effects of the drug candidate. These studies are crucial for determining the maximum tolerated dose and identifying any organ toxicity. They typically involve both acute and chronic exposure assessments in multiple animal species.

Formulation Development

Formulation development involves creating a stable and effective form of the drug that can be administered to patients. This includes determining the appropriate dosage form, such as tablets, capsules, or injectables, and ensuring the drug's stability over time.

Good Laboratory Practice (GLP)

Preclinical studies must adhere to Good Laboratory Practice (GLP) standards, which ensure the quality and integrity of the data collected. GLP compliance is essential for regulatory submissions and approval.

Regulatory Considerations

Before a drug candidate can move to clinical trials, a comprehensive Investigational New Drug (IND) application must be submitted to regulatory authorities, such as the Food and Drug Administration (FDA) in the United States. The IND application includes all preclinical data, proposed clinical trial protocols, and information on the drug's manufacturing process.

Related Pages

• Drug discovery
• Clinical trial
• Pharmacology
• Toxicology
• Good Laboratory Practice

This article is a stub related to pharmacology. You can help WikiMD by expanding it!